Gel Tech Zicam Zinc Spray Patent Infringement Charged In Quigley Suit
This article was originally published in The Tan Sheet
Executive Summary
The Quigley Corporation, manufacturer and marketer of the Cold-Eeze line of zinc lozenges, is alleging patent infringement against GumTech, Inc., GEL-Tech Industries and Gel Tech LLC related to their distribution of the Zicam homeopathic zinc nasal spray.
You may also be interested in...
Quigley v. Gum Tech
Gum Tech's motion to dismiss a patent infringement lawsuit brought by Cold-Eeze lozenges manufacturer Quigley denied by a Philadelphia federal judge March 9. The court, interpreting the '465 patent to extend to "any method of applying zinc gluconate to the lining of the mouth, tongue and throat," found disputed issues of material fact exist as to whether Gum Tech's Zicam homeopathic nasal spray infringes the patent. Quigley filed suit in November against Gum Tech and associated entities (1"The Tan Sheet" Nov. 22, 1999, p. 9). The Philadelphia court will hear arguments March 31 on Quigley's request to preliminarily enjoin the defendants from infringing its patent. In court filings, Quigley asserts it will suffer irreparable harm, in the form of lost sales and market share, if Zicam continues to be sold
Quigley v. Gum Tech
Gum Tech's motion to dismiss a patent infringement lawsuit brought by Cold-Eeze lozenges manufacturer Quigley denied by a Philadelphia federal judge March 9. The court, interpreting the '465 patent to extend to "any method of applying zinc gluconate to the lining of the mouth, tongue and throat," found disputed issues of material fact exist as to whether Gum Tech's Zicam homeopathic nasal spray infringes the patent. Quigley filed suit in November against Gum Tech and associated entities (1"The Tan Sheet" Nov. 22, 1999, p. 9). The Philadelphia court will hear arguments March 31 on Quigley's request to preliminarily enjoin the defendants from infringing its patent. In court filings, Quigley asserts it will suffer irreparable harm, in the form of lost sales and market share, if Zicam continues to be sold
Quigley v. Gum Tech
Gum Tech's motion to dismiss a patent infringement lawsuit brought by Cold-Eeze lozenges manufacturer Quigley denied by a Philadelphia federal judge March 9. The court, interpreting the '465 patent to extend to "any method of applying zinc gluconate to the lining of the mouth, tongue and throat," found disputed issues of material fact exist as to whether Gum Tech's Zicam homeopathic nasal spray infringes the patent. Quigley filed suit in November against Gum Tech and associated entities (1"The Tan Sheet" Nov. 22, 1999, p. 9). The Philadelphia court will hear arguments March 31 on Quigley's request to preliminarily enjoin the defendants from infringing its patent. In court filings, Quigley asserts it will suffer irreparable harm, in the form of lost sales and market share, if Zicam continues to be sold